Conversations in Lung Cancer Research

Conversations in Lung Cancer Research

By Thoracic Oncology Group Of Australasia (TOGA)MedicineHealth & Fitness
Download on the App Store

Conversations in Lung Cancer Research episodes

  • From Clinical Research to Leadership: A Conversation with Prof. Michael Boyer

    In this episode of Conversations in Lung Cancer Research, A/Prof Mel Moore interviews Prof Michael Boyer, AM about his extensive career in medical oncology and his current role as CEO of Chris O'Brien Lifehouse. They discuss his early interest in oncology, the influential mentors in his career, and the evolution of lung cancer treatment and research. Michael shares his perspectives on leadership in medical and research roles, the importance of building relationships, and the balance between industry-sponsored and cooperative group research. They also touch upon professional challenges, emotional resilience in oncology, and Michael's vision for the future of his career and the field of oncology.

     

    (00:00) Welcome and Introduction

    (01:04 )Guest Introduction: Professor Michael Boyer

    (02:25) Michael Boyer's Early Career and Mentorship

    (07:27) Leadership Roles and Challenges

    (11:33) Involvement in Clinical Research

    (21:03) Emotional Aspects of Oncology

    (29:38) Future of Oncology and Career Advice

    (33:06) Conclusion and Farewell

    Resources and Links:

    International Association for the Study of Lung Cancer https://www.iaslc.org/

    Chris O'Brien Lifehouse https://www.mylifehouse.org.au/

    Schwartz Rounds https://www.theschwartzcenter.org/programs/schwartz-rounds/

    ---------------

    Support TOGA

    Thank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify.

    ---------------

    Connect with TOGA

    Attend an Event: https://thoraciconcology.org.au/events/

    Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/

    Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/

    Follow Us

    LinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/

    X (Twitter): https://x.com/TOGAANZ

    Instagram: https://www.instagram.com/togaanz/

    YouTube: https://www.youtube.com/@Thoracic_Oncology

    ---------------

    Acknowledgement of Country

    The Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

    35 min
  • Introducing Conversations in Lung Cancer Research - Trailer

    In this introductory episode, Associate Professor Mel Moore, medical oncologist and education chair at TOGA, announces the evolution of TOGA podcasts to 'Conversations in Lung Cancer Research.' 

    The podcast will continue to deliver the latest breakthroughs in lung cancer research while expanding to include deeper dives and engaging discussions with experts in thoracic oncology. Listeners can look forward to unique insights from researchers, clinicians, and key thought leaders shaping the future of lung cancer care.

    ---------------

    Support TOGA

    Thank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify.

    ---------------

    Connect with TOGA

    Attend an Event: https://thoraciconcology.org.au/events/

    Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/

    Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/

    Follow Us

    LinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/

    X (Twitter): https://x.com/TOGAANZ

    Instagram: https://www.instagram.com/togaanz/

    YouTube: https://www.youtube.com/@Thoracic_Oncology

    ---------------

    Acknowledgement of Country

    The Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

    2 min
  • Navigating Resistance in ALK-Positive NSCLC Patients on TKI Therapy
    We have witnessed incredible advances in therapy since ALK was discovered in 2007, starting from the pivotal PROFILE 1001 study of crizotinib in advanced ALK positive NSCLC to present day where we now have five approved targeted agents, with increasing potency, selectivity and CNS activity with each successive generation of drug. Despite these advances in therapy, the emergence of treatment resistance in the TKI still remains one of greatest challenges in the clinic. Our TOGA podcast panel discuss the clinical and genetic factors affecting treatment choice, sequencing and resistance patterns, including oligoprogression and local therapy considerations.
    Dr Rebecca Tay, Medical Oncologist at Royal Hobart Hospital and ICON Hobart, is joined in this discussion by Professor Ben Solomon, Medical Oncologist at Peter MacCallum Cancer Centre & Board member, Scientific Chair of TOGA and Associate Professor Michael Ng, Radiation Oncologist at GenesisCare St Vincents Hospital Melbourne and Head of Stereotactic Radiotherapy at GenesisCare Victoria.
    References:
    CROWN: ascopubs.org/doi/10.1200/JCO.24.00581
    Gomez paper denovo oligomet SABR
    pubmed.ncbi.nlm.nih.gov/31067138/
    Kroeze – concurrent systemic therapy + SABR consensus
    sciencedirect.com/science/article/abs/pii/S1470204522007525
    Tsai Curb trial RCT for oligoprogression
    pubmed.ncbi.nlm.nih.gov/38104577/ ---------------
    Support TOGA
    Thank you for listening to Conversations in Lung Cancer Research. If you
    enjoyed this episode, please rate and review us on Apple Podcasts or
    Spotify.
    ---------------
    Connect with TOGA
    Attend an Event: https://thoraciconcology.org.au/events/
    Become a Member: Join the TOGA community at
    https://thoraciconcology.org.au/membership/
    Donate: Support our research and treatment initiatives at
    https://thoraciconcology.org.au/support-us/donate/
    Follow Us
    LinkedIn:
    https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/
    X (Twitter): https://x.com/TOGAANZ
    Instagram: https://www.instagram.com/togaanz/
    YouTube: https://www.youtube.com/@Thoracic_Oncology
    ---------------
    Acknowledgement of Country
    The Thoracic Oncology Group of Australasia Limited acknowledges
    Traditional Owners of Country throughout Australia and recognises the
    continuing connection to lands, waters and communities. We pay our
    respect to Aboriginal and Torres Strait cultures; and to Elders past and
    present.
    27 min
  • Hit It With Your Best Shot- The Case for IO in Early-Stage NSCLC in a Once in a Lifetime World

    Editor's Note (June 2026): This episode was recorded prior to Australia's broad PBS listing of nivolumab and ipilimumab, which has removed the previous "once in a lifetime" restriction on immunotherapy. For the latest discussion on these changes and what they mean for lung cancer care, see our recent Conversations in Lung Cancer Research episodes on the broad immunotherapy listing.

    ---------------

    Support TOGA

    Thank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify.

    ---------------

    Connect with TOGA

    Attend an Event: https://thoraciconcology.org.au/events/

    Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/

    Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/

    Follow Us

    LinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/

    X (Twitter): https://x.com/TOGAANZ

    Instagram: https://www.instagram.com/togaanz/

    YouTube: https://www.youtube.com/@Thoracic_Oncology

    ---------------

    Acknowledgement of Country

    The Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

    28 min
  • Large-Cell Neuroendocrine Carcinoma of the Lung (LCNEC): Challenges in Diagnosis and Treatment
    In this episode, we discuss the clinical and diagnostic markers when identifying a rare sub type of NSCLC, large-cell neuroendocrine carcinomas (LC-NEC), and provide insights into the management of these patients and future treatment developments.
    Associate Professor Rachel Wong, Deputy Director Oncology Eastern Health and Medical Oncologist at Epworth East in Melbourne is joined by Dr Patrick Hosking, Senior Histopathologist at Eastern Health Pathology; Dr Mal Itchins, Thoracic Medical Oncologist at Royal North Shore Hospital and Chris O'Brien LifeHouse in Sydney and Dr Sagun Parakh, Medical Oncologist at the Austin Hospital, Lung Cancer Lead.
    https://www.omico.com.au/our-programs/cancer-screening-program-casp/ ---------------
    Support TOGA
    Thank you for listening to Conversations in Lung Cancer Research. If you
    enjoyed this episode, please rate and review us on Apple Podcasts or
    Spotify.
    ---------------
    Connect with TOGA
    Attend an Event: https://thoraciconcology.org.au/events/
    Become a Member: Join the TOGA community at
    https://thoraciconcology.org.au/membership/
    Donate: Support our research and treatment initiatives at
    https://thoraciconcology.org.au/support-us/donate/
    Follow Us
    LinkedIn:
    https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/
    X (Twitter): https://x.com/TOGAANZ
    Instagram: https://www.instagram.com/togaanz/
    YouTube: https://www.youtube.com/@Thoracic_Oncology
    ---------------
    Acknowledgement of Country
    The Thoracic Oncology Group of Australasia Limited acknowledges
    Traditional Owners of Country throughout Australia and recognises the
    continuing connection to lands, waters and communities. We pay our
    respect to Aboriginal and Torres Strait cultures; and to Elders past and
    present.
    24 min
  • Management of Limited-Stage Small Cell Lung Cancer (LS-SCLC)

    ---------------

    Support TOGA

    Thank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify.

    ---------------

    Connect with TOGA

    Attend an Event: https://thoraciconcology.org.au/events/

    Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/

    Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/

    Follow Us

    LinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/

    X (Twitter): https://x.com/TOGAANZ

    Instagram: https://www.instagram.com/togaanz/

    YouTube: https://www.youtube.com/@Thoracic_Oncology

    ---------------

    Acknowledgement of Country

    The Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

    19 min
  • NTRK1, 2,3 And Other Rare Mutations In NSCLC
    In this TOGA podcast, we provide an overview of the treatment options for rare subtypes of oncogene driven NSCLC that are now readily identified in the MBS-reimbursed small gene panel including NTRK1, 2,3 and other rare mutations in NSCLC. The importance of testing all patients is discussed as well as what to do when resistance occurs.
    Associate Professor Steven Kao, Medical Oncologist from Chris O’Brien Lifehouse and Clinical Associate Professor Sydney Medical School, Faculty of Medicine and Health is joined by Professor Wendy Cooper, senior staff specialist in Tissue Pathology and Diagnostic Oncology at Royal Prince Alfred Hospital in Sydney, Anatomical Clinical Stream Lead for NSW Health Pathology, a Clinical Professor at the University of Sydney and a Conjoint Professor at the University of Western Sydney and also Professor Ben Solomon head of the lung Medical Oncology Service and a Group Leader of the Molecular Therapeutics and Biomarkers Laboratory in the Research Division at Peter MacCallum Cancer Centre as well as a Founding Board member of TOGA. ---------------
    Support TOGA
    Thank you for listening to Conversations in Lung Cancer Research. If you
    enjoyed this episode, please rate and review us on Apple Podcasts or
    Spotify.
    ---------------
    Connect with TOGA
    Attend an Event: https://thoraciconcology.org.au/events/
    Become a Member: Join the TOGA community at
    https://thoraciconcology.org.au/membership/
    Donate: Support our research and treatment initiatives at
    https://thoraciconcology.org.au/support-us/donate/
    Follow Us
    LinkedIn:
    https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/
    X (Twitter): https://x.com/TOGAANZ
    Instagram: https://www.instagram.com/togaanz/
    YouTube: https://www.youtube.com/@Thoracic_Oncology
    ---------------
    Acknowledgement of Country
    The Thoracic Oncology Group of Australasia Limited acknowledges
    Traditional Owners of Country throughout Australia and recognises the
    continuing connection to lands, waters and communities. We pay our
    respect to Aboriginal and Torres Strait cultures; and to Elders past and
    present.
    22 min
  • Decoding Perioperative Immunotherapy In NSCLC
    In this TOGA podcast, we provide an overview of the recent neoadjuvant, adjuvant, and perioperative IO data, the options and considerations for treatment and the current reimbursement landscape. Dr Pei Ni Ding, Medical Oncologist from Westmead and Nepean Hospitals Sydney, is joined by Dr Samantha Bowyer, Medical Oncologist from Sir Charles Gairdner Hospital in Perth and Mr Naveed Alam, Thoracic Surgeon from St Vincents, Epworth and Monash in Melbourne.
    Many emerging treatments are discussed in this podcast, and clinicians are reminded that oncology access programs are listed in the medicines access portal https://www.medicinesap.com/ ---------------
    Support TOGA
    Thank you for listening to Conversations in Lung Cancer Research. If you
    enjoyed this episode, please rate and review us on Apple Podcasts or
    Spotify.
    ---------------
    Connect with TOGA
    Attend an Event: https://thoraciconcology.org.au/events/
    Become a Member: Join the TOGA community at
    https://thoraciconcology.org.au/membership/
    Donate: Support our research and treatment initiatives at
    https://thoraciconcology.org.au/support-us/donate/
    Follow Us
    LinkedIn:
    https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/
    X (Twitter): https://x.com/TOGAANZ
    Instagram: https://www.instagram.com/togaanz/
    YouTube: https://www.youtube.com/@Thoracic_Oncology
    ---------------
    Acknowledgement of Country
    The Thoracic Oncology Group of Australasia Limited acknowledges
    Traditional Owners of Country throughout Australia and recognises the
    continuing connection to lands, waters and communities. We pay our
    respect to Aboriginal and Torres Strait cultures; and to Elders past and
    present.
    22 min
  • Decoding Perioperative Immunotherapy in NSCLC
    In this TOGA podcast, we provide an overview of the recent neoadjuvant, adjuvant, and perioperative IO data, the options and considerations for treatment and the current reimbursement landscape. Dr Pei Ni Ding, Medical Oncologist from Westmead and Nepean Hospitals Sydney, is joined by Dr Samantha Bowyer, Medical Oncologist from Sir Charles Gairdner Hospital in Perth and Mr Naveed Alam, Thoracic Surgeon from St Vincents, Epworth and Monash in Melbourne.
    Many emerging treatments are discussed in this podcast, and clinicians are reminded that oncology access programs are listed in the medicines access portal https://www.medicinesap.com/
    22 min
  • Access to New Medicines: Which Surrogate Endpoints Matter
    Do we need to evolve the bar on evidence required for drug reimbursement? The gold standard endpoint for assessing the benefit of anti-cancer drugs has been overall survival (OS) however, more recently, there has been a trend toward using surrogate clinical trial endpoints such as progression free survival (PFS) and event-free survival (EFS). As treatments improve and patients are living longer, using OS as a primary endpoint can mean a longer time until a result is obtained. In this podcast, Dr Rebecca Tay, Medical Oncologist at Royal Hobart Hospital and ICON, discusses the critical role of improvement in quality of life in assessing drugs that are funded on the PBS, the nuances around clinical trial endpoints and the need for surrogate endpoints that accurately predict for OS and a reimbursement system that brings beneficial treatments to patients faster. Professor Nick Pavlakis, Chair of TOGA and Medical Oncologist at Royal North Shore Hospital and Genesis Care and Dr Deme Karikios, Immediate Past Chair of MOGA and Medical Oncologist from Nepean Hospital Sydney join the conversation.
    https://jamanetwork.com/journals/jama/article-abstract/2817337 ---------------
    Support TOGA
    Thank you for listening to Conversations in Lung Cancer Research. If you
    enjoyed this episode, please rate and review us on Apple Podcasts or
    Spotify.
    ---------------
    Connect with TOGA
    Attend an Event: https://thoraciconcology.org.au/events/
    Become a Member: Join the TOGA community at
    https://thoraciconcology.org.au/membership/
    Donate: Support our research and treatment initiatives at
    https://thoraciconcology.org.au/support-us/donate/
    Follow Us
    LinkedIn:
    https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/
    X (Twitter): https://x.com/TOGAANZ
    Instagram: https://www.instagram.com/togaanz/
    YouTube: https://www.youtube.com/@Thoracic_Oncology
    ---------------
    Acknowledgement of Country
    The Thoracic Oncology Group of Australasia Limited acknowledges
    Traditional Owners of Country throughout Australia and recognises the
    continuing connection to lands, waters and communities. We pay our
    respect to Aboriginal and Torres Strait cultures; and to Elders past and
    present.
    25 min

About Conversations in Lung Cancer Research

From the publisher's feed

Welcome to Conversations in Lung Cancer Research, presented by TOGA, your go-to podcast for in-depth insights into lung cancer. Tune in for conversations with leading experts, inspiring stories, and…

More shows like Conversations in Lung Cancer Research

Lung Cancer Considered by IASLC

Lung Cancer Considered

26 Listeners

Lung Cancer Rx by Oncology News Central

Lung Cancer Rx

3 Listeners